Business Info Developer ConsultantCarelon Research, Inc., United States
Disclosure information not submitted.
2C-06 - Analyzing Incidence of Adverse Events Commonly Assessed in Vaccine Safety Studies in Medicaid versus Commercially-Insured Populations in Carelon Research’s OMOP Data
Sunday, August 24, 20254:45 PM - 5:00 PM ET
5C-06 - Incidence Rates of Myocarditis/Pericarditis after Pfizer-BioNTech COVID-19 Vaccine in the United States: Interim Results From a Postapproval Safety Study, Primary Series Analysis
Tuesday, August 26, 20259:45 AM - 10:00 AM ET
